Brind.
  1. Ultragenyx Pharmaceutical is leading the Orbit study, and Dr. Denise Scots-Knight serves as the Chief Executive Officer of the involved entities.

The Orbit study, involving Ultragenyx Pharmaceutical and ORBIT, is evaluating the drug UX143 for osteogenesis imperfecta.

2 reports, 2 independent Updated Jul 10
Gone quiet Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

The Orbit study, involving Ultragenyx Pharmaceutical and ORBIT, is evaluating the drug UX143 for osteogenesis imperfecta.

Who's involved

What this event is mainly about
Ultragenyx PharmaceuticalORBIT

How it developed

Newest first. Tap a step to see who reported it.
  1. The Orbit study is evaluating UX143 for osteogenesis imperfecta, with Ultragenyx and ORBIT as partners.1 source
  2. Announced joint Phase 3 study for UX143, following successful Phase 2/3 evaluation.1 source

Keep exploring

Part of

Ultragenyx Pharmaceutical is leading the Orbit study, and Dr. Denise Scots-Knight serves as the Chief Executive Officer of the involved entities. All 1 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • ZacksRARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year End Ultragenyx Pharmaceutical RARE and partner, Mereo BioPharma MREO, have reported an update on the progress of the mid-to-late-sta
  • GlobeNewswireUltragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final Analysis Data from Orbit and Cosmic studies expected around the end of the year NOVA